FMOD and B-cell chronic lymphocytic leukemia: Nine low expressed DMEGs were selected with hypermethylated in promoter and hypomethylated in body, such as ADAMTS17, and 83 high expressed DMEGs were selected with both hypomethylated in promoter and body, such as ZAP70, FMOD, PAX9. 48 CLL cases were characterized into three subgroups based on SVM model.